D.M. KHASANOVA¹, Z.A. ZALYALOVA¹, R.R. AZAROVA³, T.YU. SOKOLENKO³, S.E. MUNASIPOVA^1, 2, L.A. YAKOVLEVA³

 ¹Republic Clinical-diagnostic Center for extrapyramidal pathology and botulinum therapy, Russian Federation, Kazan

²Kazan State Medical University of the Ministry of the Russian Federation, Kazan

³Hospital for veterans of wars, Russian Federation, Kazan

 Contact details:

Khasanova D.M. — Ph. D. (medicine), neurologist

Address: 5 Isaeva St., Kazan, Russian Federation, 420012, tel.: +7-905-039-88-95, e—mail: diana.khasanova1987@gmail.com

 Campocormia — an abnormal posture, which is characterized by reversible pathological bending of the trunk forward, occurs in various diseases of the nervous system. The most common cause of camptocormia is Parkinson’s disease. There is no universally accepted method for treating camptocormia, but a number of authors recommend stopping the use of dopamine receptor agonists and chemodenervation with botulinum toxins of type A. The article presents 3 cases of treating camptocormia, caused by various neurological diseases, with botulinum toxin type A drugs (incobotulotoxin A, onbotulotoxin A doses of 400 U and abobotulotoxin A in a dose of 2000 U). Between 2016 and 2019, 14 patients with Parkinson’s disease (n = 11), generalized dystonia (n = 1), and post-traumatic spasticity with dystonia (n = 2) were injected with botulinum toxin type A into the iliopsoas muscle. Prior to this, all patients underwent injections of botulinum toxins into the abdominal muscles without a pronounced positive effect. Injections were performed under the control of X-ray computed tomography (CT) using the dorsal method. Clinically significant improvement after botulinum toxin injection was observed in 41.6% of patients with Parkinson’s disease, in all patients with generalized dystonia, and in a patient with post-traumatic camptocormia. A positive patient response to botulinum toxin suggests a dystonic etiology of camptocormia in these patients.

Key words: camptocormia, Parkinson’s disease, botulinum toxin, botulinum therapy.

(For citation: Zalyalova Z.A., Khasanova D.M., Azarova R.R., Sokolenko T.Yu., Munasipova S.E., Yakovleva L.A. Treatment of camptocormia with botulinic toxin. Observations and literature review. Practical Medicine. 2019. Vol. 17, № 7, P. 158-162)

REFERENCES

1. Kosbab S.P. Camptocormia-a rare case in the female. Am J Psychiatry, 1961, vol. 117, pp. 839–840.
2. Sandler S.A. Camptocormia: a functional condition of the back in neurotic soldiers. Arch Neurol Psychiatry, 1946, vol. 55, pp. 158–160.
3. Srivanitchapoom P., Hallet M. Camptocormia in Parkinson’s disease: definition, epidemiology, pathogenesis and treatment modalities. J Neurol Neurosurg Psychiatry, 2015, vol. 0, pp. 1–11.
4. Finsterer J., Strobl W. Presentation, Etiology, Diagnosis, and Management of Camptocormia. European Neurology, 2010, vol. 64 (1), pp. 1–8.
5. Margraf N. et al. Clinical Definition of Camptocormia in Parkinson’s Disease. Movement Disorders Clinical Practise, 2016.
6. Margraf N. et al. Pathophysiological Concepts and Treatment of Camptocormia. Journal of Parkinson’s disease, 2016, vol. 6, pp. 485–501.
7. Nakayama Y., Miwa H. Drug-induced camptocormia: a lesson regarding vascular Parkinsonism. Internal medicine, 2012, vol. 51, pp. 2843–2844.
8. Jankovic J. An update on new and unique uses ofbotulinum toxin in movement disorders. Toxicon, 2017.
9. Djaldetti R., Melamed E. Camptocormia in Parkinson’s disease: new insights. J Neurol Neurosurg Psychiatry, 2006, vol. 77, p. 1205.
10. Margraf N. et al. Consensus for the measurement of the camptocormia angle in the standing patient. Parkinsonism and Related Disorders, 2018.
11. Margraf N. et al. Trunk muscle activation pattern in parkinsonian camptocormia as revealed with surface electromyography. Parkinsonism Relat Disord, 2017, vol. 44, pp. 44–50.
12. Furusawa Y. et al. Role of the external oblique muscle in upper camptocormia for patients with Parkinson’s disease. Mov Disord, 2012, vol. 27, pp. 802–803.
13. Mills R., Bahroo L., Pagan F. An update on the use of botulinum toxin therapy in Parkinson’s disease. Curr. Neurol. Neurosci. Rep, vol. 15 (1), p. 511.
14. Bertram K., Stirpe P., Colosimo C. Treatment of camptocormia with botulinum toxin. Toxicon, 2015, pp. 1–6.